GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 42.63

Change

+6.79 (+18.95)%

Market Cap

USD 4.85B

Volume

4.24M

Analyst Target

USD 110.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-9.79 (-2.24%)

USD 35.55B
NTRA Natera Inc

+7.39 (+5.57%)

USD 21.03B
ICLR ICON PLC

-6.94 (-3.80%)

USD 16.66B
ILMN Illumina Inc

-1.45 (-1.69%)

USD 14.06B
MEDP Medpace Holdings Inc

-11.54 (-3.42%)

USD 9.97B
EXAS EXACT Sciences Corporation

+0.92 (+2.05%)

USD 9.13B
RDNT RadNet Inc

+1.18 (+2.46%)

USD 4.54B
SHC Sotera Health Co

-0.43 (-3.64%)

USD 3.91B
VCYT Veracyte Inc

+0.72 (+2.37%)

USD 3.18B
WGS GeneDx Holdings Corp.

-2.49 (-2.78%)

USD 2.75B

ETFs Containing GH

ARKG:LSE ARK Genomic Revolution UC.. 5.83 % 0.00 %

-0.05 (-1.31%)

USD 9.33M
ARCG:LSE ARK Genomic Revolution UC.. 5.01 % 0.00 %

-3.88 (-1.31%)

USD 9.51M
DOCG:LSE L&G Healthcare Breakthrou.. 2.39 % 0.00 %

-23.55 (-1.31%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.39 % 0.00 %

-0.27 (-1.31%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.30 % 0.00 %

-0.17 (-1.31%)

USD 0.07B
FESM Fidelity Covington Trust 0.70 % 0.00 %

+0.16 (+-1.31%)

USD 2.22B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

+0.46 (+-1.31%)

USD 1.32B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+0.20 (+-1.31%)

USD 0.43B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.11 (-1.31%)

USD 0.05B
XHS SPDR® S&P Health Care Se.. 0.00 % 0.35 %

+0.14 (+-1.31%)

USD 0.08B
QBTL:CA AGFiQ US Market Neutral A.. 0.00 % 0.00 %

-0.46 (-1.31%)

CAD 0.26B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.54% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.54% 92% A 95% A
Trailing 12 Months  
Capital Gain 128.70% 98% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.70% 98% N/A 96% N/A
Trailing 5 Years  
Capital Gain -36.38% 41% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.38% 38% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -16.07% 35% F 16% F
Dividend Return -16.07% 35% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.69% 65% D 39% F
Risk Adjusted Return -33.00% 31% F 19% F
Market Capitalization 4.85B 86% B+ 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector